Early switch maintenance in gastric cancer: who benefits most?

First-line treatments have historically relied on fluoropyrimidine and platinum agents, but more recent approaches incorporate biomarker-guided targeted therapies, including those based on PD-L1 combined positive score, mismatch repair status or microsatellite instability, and claudin-18.2 expressio...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The lancet oncology 2024-12, Vol.25 (12), p.1508-1509
Hauptverfasser:	Sakakida, Tomoki, Kadowaki, Shigenori
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers Cancer therapies Chemotherapy Disease control Gastric cancer Medical prognosis Microsatellite instability Mismatch repair Paclitaxel Patients PD-L1 protein Response rates Survival
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!